Format

Send to

Choose Destination
Clin Infect Dis. 2017 May 15;64(10):1317-1325. doi: 10.1093/cid/cix110.

Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses.

Author information

1
Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan.
2
Third Division of Viral Vaccines, National Institutes for Food and Drug Control, and.
3
Ministry of Health Key Laboratory for Medical, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing.
4
No. 5 Department of Biological Products, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan.
5
Vaccine Clinical Research Center, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, and.
6
No. 4 Department of Biological Products, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, China.

Erratum in

Abstract

Background:

A Sabin strain-based inactivated poliomyelitis vaccine (Sabin-IPV) is the rational option for completely eradicating poliovirus transmission. The neutralizing capacity of Sabin-IPV immune serum to different strains of poliovirus is a key indicator of the clinical protective efficacy of this vaccine.

Methods:

Sera collected from 500 infants enrolled in a randomized, blinded, positive control, phase 2 clinical trial were randomly divided into 5 groups: Groups A, B, and C received high, medium, and low doses, respectively, of Sabin-IPV, while groups D and E received trivalent oral polio vaccine and Salk strain-based IPV, respectively, all on the same schedule. Immune sera were collected after the third dose of primary immunization, and tested in cross-neutralization assays against 19 poliovirus strains of all 3 types.

Results:

All immune sera from all 5 groups interacted with the 19 poliovirus strains with various titers and in a dose-dependent manner. One type 2 immunodeficiency-associated vaccine-derived poliovirus strain was not recognized by these immune sera.

Conclusions:

Sabin-IPV vaccine can induce protective antibodies against currently circulating and reference wild poliovirus strains and most vaccine-derived poliovirus strains, with rare exceptions.

Clinical Trials Registration:

NCT01056705.

KEYWORDS:

Sabin-IPV; cross neutralization; immune serum; polioviruses.

PMID:
28419204
DOI:
10.1093/cid/cix110
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center